How can we move beyond "the more data we have, the less we know" (as one participant put it) to real success using data for better patient care and clinic efficiency?

The 2016 Biomax Symposium offered real-world solutions to overcome the challenges of using complex data in a clinical environment: from the collection of Big Data and guaranteeing data security in daily practice, to fostering feedback between clinical data and research, to ultimately learning from the data to make better, evidence-based treatment decisions.

Held near Munich, Germany on 24 June 2016, the Biomax Symposium gathered renowned experts in computational biology, clinic management, pharma, public health, Big Data mining, neurology, knowledge management, and more to discuss their experiences and share their expertise.


Thank you to all speakers for their insightful presentations

The invited speakers offered a well-rounded scope of talks: from detailed projects to predict dementia, determine epilepsy surgery targets, manage public health reactions to infectious disease, or predict insulin sensitivity with Big Data; to data safety, real-world implementation and digitalization in clinics and drug development, and "big picture" talks on the state of the art, the impact of results, and future possibilities.

We invite you to visit the symposium website to explore the presentations.


"All new hospitals need to be digital."
The symposium’s panel discussion was a discerning conversation for those ready to go digital. The panel covered why the German healthcare system falls behind other countries in investing in health IT and explored ideas from successful clinics in other countries. While the invited experts and representatives from hospitals, public health and government agreed on the need for and many benefits of digitalization and personalized medicine, they offered diverse ways it can be achieved: small steps, gradual change, new standards or "disruptive" external forces.


Overheard at the symposium
Do we need 'creative destruction' of clinical IT?
Can we break through the current limitations in Big Data with advances in computational chemistry?
The benefits of digital data go far beyond financials.
Outcome-oriented decisions ARE economical.
The positive impact on patient treatment and in particular patient safety are enormous.
How much harm do we set up for lack of digitization? In comparison to resistant bacteria or incorrect medicine?
90% of decisions can be made based on shared information rather than new examinations.
Digitalization offers more time and the possibility for doctors to reflect.


CONCLUSION
The 2016 Biomax Symposium presented what happens when leaders in clinics, hospitals, research and government are bold enough to initiate digitalization, go paperless, and integrate big and complex data into clinical practice. The examples ranged from small-scale to clinic-wide adoption — but the measurable benefits were clear:
  • Better patient outcomes
  • Less error-prone delivery of medicine
  • More time for clinical staff to interact with patients and reflect on their cases
  • Real economic savings
  • Improved clinic-wide efficiency
  • And more
The 2016 Biomax Symposium was thought-provoking and valuable. We look forward to implementing the lessons learned with our clients — and in our technologies — to improve how big and complex data are used in clinical practice.

Contact Biomax to learn more about our health informatics solutions.


CONTACT BIOMAX TODAY
Germany
Robert-Koch Str. 2
D-82152 Planegg
+49 89 895574-0

United Kingdom
93 Boss House
2 Boss Street
London SE1 2PT
+44 7832 965 326
United States
1101 Highway 69
Suite #5
New Glarus, WI 53574
+1 608 636 2222
Biomax Website +49 89 895574-0 info@biomax.com
Biomax is a registered trademark of Biomax Informatics AG in Germany and other countries.
Biomax Informatics AG
Registered Office (Sitz der Gesellschaft): Planegg, Germany
Court of Registration (Registergericht): AG München, HRB 134442
CEO (Vorstandsvorsitzender): Dr. Klaus Heumann
Chairman of the Supervisory Board (Vorsitzender des Aufsichtsrats): Prof. Dr. Hans-Werner Mewes